Comparative Pharmacology
Head-to-head clinical analysis: DEXTROMETHORPHAN POLISTIREX versus TESSALON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROMETHORPHAN POLISTIREX versus TESSALON.
DEXTROMETHORPHAN POLISTIREX vs TESSALON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
Benzonatate is a local anesthetic structurally related to tetracaine that inhibits pulmonary stretch receptors and reduces the cough reflex by decreasing the sensitivity of vagal afferent fibers in the respiratory tract.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
100 mg orally three times daily as needed for cough. Maximum 600 mg/day.
None Documented
None Documented
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
Terminal elimination half-life is approximately 12-15 hours in adults; significant interindividual variability. No accumulation with q6h dosing.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Renal: <5% unchanged; primary route is hepatic metabolism with metabolites excreted renally and fecally; exact biliary/fecal % not established in humans.
Category C
Category C
Antitussive
Antitussive